Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H5ER
|
|||
| Former ID |
DIB008325
|
|||
| Drug Name |
MLN-591RL
|
|||
| Synonyms |
HuJ591; J591; MLN-5591RL; MLN-591; ATG-J591:RC; Anti-PSMA, Millennium; Lutetium-177-J591; Yttrium-90-J591; Anti-PSMA, Millennium/BZL Biologics; Lutetium-177-MLN-591; Yttrium-90-MLN-591; 111In-J591; 177Lu-J591; 177Lu-MLN-591; 90Y-J591; 90Y-MLN-591
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 2 | [1] | |
| Company |
Millennium Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glutamate carboxypeptidase II (GCPII) | Target Info | . | [2] |
| KEGG Pathway | Alanine, aspartate and glutamate metabolism | |||
| Metabolic pathways | ||||
| Vitamin digestion and absorption | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| Reactome | Amino acid synthesis and interconversion (transamination) | |||
| WikiPathways | One Carbon Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00195039) Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015 Apr 29;5:28. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.